...

Conference Report

Highlights in Viral Hepatitis: CCO Independent Conference Report on the 2007 Digestive Disease Week

Source: CCO Independent Conference Coverage of the 2007 Digestive Disease Week*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Highlights in Viral Hepatitis: CCO Independent Conference Report on the 2007 Digestive Disease Week


Faculty:

Mark S. Sulkowski, MDKris V. Kowdley, MD, FACP
  • Mark S. Sulkowski, MD
  • Kris V. Kowdley, MD, FACP

CREDIT INFORMATION

Release Date: 07/30/07

Expiration Date: 07/29/08


Physicians: maximum of 1.25 AMA PRA Category 1 Credits

Status: Please log in to view status


Begin the Conference Report

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the results of recent studies of diagnostic tests for viral hepatitis and its complications, including fibrosis, cirrhosis, and hepatocellular carcinoma
  • Discuss the use of FDA-approved agents for the treatment of patients with chronic hepatitis B or chronic hepatitis C and strategies for managing their adverse effects
  • Discuss results of clinical studies of investigational treatments for chronic hepatitis B and C

Topics covered include:

  • 14-Day R1626 Monotherapy in Treatment-Naive Hepatitis C Virus Genotype 1 Patients
  • 14-Day HCV-796 Monotherapy in Treatment-Naive HCV Patients
  • Pancaspase Inhibitor PF-03491390
  • Impact of Predosing of Taribavirin on Sustained Virologic Response Rates
  • Rosuvastatin Therapy Does Not Impact HCV RNA Levels
  • Retreatment of Patients Who Do Not Achieve SVR With Peginterferon and Ribavirin Therapy
  • Impact of HCV Therapy With or Without SVR on Liver Histology
  • HCV-Positive and -Negative Hepatic Transplantations Into HCV-Positive Patients
  • Implementation of HCV Therapy in a Real-World Setting
  • Darbepoetin Alfa and Filgrastim Treatments for Cytopenias
  • Natural History of Hepatitis B
  • Treatments for Chronic Hepatitis B
  • Prophylactic Use of Lamivudine During Chemotherapy


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.